Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
This one-of-a-kind innovation challenge is aimed at addressing the challenges faced by healthcare providers in digital technology adoption
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
